Germany · Delayed Price · Currency is EUR Cherry SE Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 3% year-over-year to EUR 40 million, with adjusted EBITDA loss narrowing to minus EUR 4 million due to cost reductions and margin improvements. Project Blossom and inventory normalization are key to future growth, while the Digital Health & Solutions divestment and recent capital raise strengthen the financial outlook.
-
Q1 2026 showed operational improvements, with strong DH&S growth and improved EBITDA margin despite lower group revenue. Project Blossom targets profitability by 2027, supported by cost reductions, a reverse share split, and ongoing M&A.
Fiscal Year 2025
-
Revenue declined 15% in 2025 due to divestments and weak Components, but like-for-like sales grew 4.7%. Inventory and costs were significantly reduced, with margin recovery in Peripherals and strong Digital Health growth. Strategic review for a major segment sale is ongoing.
-
Revenue and profitability declined sharply in H1 2025 due to restructuring and weak demand, but liquidity improved through asset sales and inventory reduction. Digital health shows strong momentum, and full-year guidance was lowered, with a focus on cash flow and operational discipline.
-
Restructuring includes shifting switch production to China, major SKU reduction, and a new focus on high-margin peripherals and digital health. 2025 guidance targets EUR 105–120 million revenue and 3–6% EBITDA margin, with margin recovery expected in H2.
Fiscal Year 2024
-
2024 revenue fell short of forecasts due to weak Americas and switch business, but digital health saw strong growth and cost controls led to positive Q4 free cash flow. Strategic restructuring and new partner programs aim to drive recovery, with a focus on returning to profitability in 2025.
-
Q3 2024 saw a sharp revenue and EBITDA decline, mainly due to weak German demand and internal issues, prompting restructuring and cost-cutting. Digital Health showed strong growth, while Gaming and Office Peripherals and Components lagged. Full-year guidance was lowered.
-
H1 2024 saw improved profitability and strong growth in Digital Health, offsetting declines in other segments. Inventory and cost controls strengthened the balance sheet, while guidance for FY 2024 is maintained despite macroeconomic headwinds and logistical risks.